The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - TP Therapeutics
Honoraria - ARIAD/Takeda; AstraZeneca; Foundation Medicine; Genentech/Roche; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Foundation Medicine; Ignyta; Novartis; Pfizer; Roche/Genentech; Takeda; TP Therapeutics
Speakers' Bureau - AstraZeneca; Genentech; Takeda
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
 
Leena Gandhi
Consulting or Advisory Role - AstraZeneca; Hengrui Pharmaceutical ; Ignyta; Merck Sharp & Dohme; Roche/Genentech; Syndax
Research Funding - Bristol-Myers Squibb
 
Shirish M. Gadgeel
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Pfizer
Speakers' Bureau - AstraZeneca
Research Funding - ACEA Biosciences (Inst); Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Halozyme (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck; Merck (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - ARIAD/Takeda; Genentech/Roche
 
Fabrice Barlesi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche/Genentech
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Novartis; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Hansoh; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Yuhan
 
Luigi De Petris
Honoraria - Proacta
Research Funding - AstraZeneca (Inst)
Expert Testimony - Boehringer Ingelheim
 
Dong-Wan Kim
No Relationships to Disclose
 
Ramaswamy Govindan
Honoraria - Boehringer Ingelheim; Genentech/Abbvie
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech/Roche; GlaxoSmithKline; Inivata; Merck Serono; Novartis; Pfizer
Research Funding - Abbvie (Inst); Bayer (Inst); GlaxoSmithKline (Inst); MethylGene (Inst)
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Celgene; Genentech; GlaxoSmithKline; Merck
 
Anne-Marie C. Dingemans
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Lucio Crino
No Relationships to Disclose
 
Lena Herve
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Lilly; Roche/Genentech
 
Sanjay Popat
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Guardant Health; Lilly; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Novartis; Pfizer; Roche
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Epizyme (Inst); Lilly (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme
 
Jin Seok Ahn
Honoraria - Bristol-Myers Squibb; Eisai; Janssen; Menarini; Roche
Consulting or Advisory Role - Boehringer Ingelheim
 
Eric Dansin
Honoraria - BMS Brazil; Novartis; Roche
Consulting or Advisory Role - MSD
Research Funding - Roche
Travel, Accommodations, Expenses - BMS Brazil; MSD; Pierre Fabre
 
Ali Hassan Zeaiter
Employment - Fabre-Kramer
Leadership - Fabre-Kramer
Stock and Other Ownership Interests - Fabre-Kramer
 
Barbara Müller
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Hrefna Johannsdottir
Employment - Fabre-Kramer
Stock and Other Ownership Interests - Fabre-Kramer
Travel, Accommodations, Expenses - Fabre-Kramer
 
Bogdana Balas
Employment - Fabre-Kramer; Fabre-Kramer (I)
Stock and Other Ownership Interests - Fabre-Kramer
 
Peter N. Morcos
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Alice Shaw
Honoraria - Genentech/Roche; Ignyta; Novartis; Pfizer
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Genentech/Roche; Ignyta; KSQ Therapeutics; LOXO; Natera; Novartis; Pfizer; Takeda
Research Funding - Genentech; Novartis; Pfizer; Roche